A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Status:
Withdrawn
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase III study is to evaluate the safety and efficacy of the combination
of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing
the number of polyps in patients with familial adenomatous polyposis (FAP).